Print Friendly and PDF
Today’s consumer tip: Don’t put flammable items on the top of the stove
Empty nesters want kids to move out and move on

FDA issues warning about IV antibiotic tigecycline

The U.S. Food and Drug Administration is issuing a warning of an increased risk of death when intravenous Tygacil or tigecycline is used for FDA-approved or non-approved uses. 

Tigecycline_structure.svgA new boxed warning about this risk will be added to the tigecycline drug label and included in the Warnings and Precautions and the Adverse Reactions sections of the label. A boxed warning is the strongest warning given to a drug. 

The FDA approved Tigecycline in 2005 to treat complicated skin infections and intra-abdominal infections and in 2009 to treat community-acquired pneumonia.

Public Citizen, a citizens’ advocacy organization, welcomes the FDA’s announcement that the agency finally has approved a new black box warning for tigecycline.

“It’s troubling that the agency took so long to require a black box warning on the drug label for this antibiotic, particularly since data demonstrating the increased mortality risk with the drug had been known to the agency since at least 2010,” said Michael Carome, director, Public Citizen’s Health Research Group.

In 2010, the FDA issued a safety alert to health care professionals informing them of the increased mortality rate associated with the use of intravenous tigecycline compared to that of other antibiotics, said Carome.

“The agency said then that alternatives to tigecycline should be considered in patients with serious infections,” he said. “The FDA also required in 2010 that the drug label be modified to include data about the increased mortality risk, but this information was not placed prominently in a black box warning, and it failed to describe appropriate restrictions on use of the drug.”

Public Citizen requested the addition of a black box warning to tigecycline in an October 2011 citizen petition to the FDA.

Given the about 30 percent higher rate of mortality in subjects receiving tigecycline as well the significantly higher rates of failures to cure serious infections, the failure of the FDA to require a black box warning years ago is inexcusable, Carome said.

Copyright 2013, Rita R. Robison, Consumer Specialist


Feed You can follow this conversation by subscribing to the comment feed for this post.

Verify your Comment

Previewing your Comment

This is only a preview. Your comment has not yet been posted.

Your comment could not be posted. Error type:
Your comment has been posted. Post another comment

The letters and numbers you entered did not match the image. Please try again.

As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.

Having trouble reading this image? View an alternate.


Post a comment

Your Information

(Name and email address are required. Email address will not be displayed with the comment.)